Medicare does not cover Wegovy when it’s prescribed solely for weight loss. Federal law has long prohibited Medicare Part D from paying for drugs used for weight management. However, a important shift happened in March 2024: the FDA approved Wegovy for a second use, reducing the risk of heart attacks, strokes, and cardiovascular death in adults who already have heart disease and are living with obesity or overweight. That cardiovascular indication opened a potential pathway for Medicare coverage, since the prescription is no longer just for weight loss.
Why Medicare Historically Excluded Wegovy
The Social Security Act contains a specific exclusion preventing Medicare Part D plans from covering drugs used for weight loss or weight gain. This blanket ban has been in place for years and applies to all anti-obesity medications, not just Wegovy. It means that even if your doctor prescribes Wegovy and you have a Part D plan, your plan cannot reimburse the cost if the stated purpose is losing weight.
HHS data confirms this exclusion was enforced in practice: Wegovy showed zero Part D claims in 2023. Some Medicare enrollees may have used the drug during that period, but they paid entirely out of pocket rather than through their Part D benefit.
The Cardiovascular Indication Changes Things
In March 2024, the FDA approved Wegovy as the first weight loss medication also indicated to prevent life-threatening cardiovascular events. Specifically, it was approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults who have established cardiovascular disease and either obesity or overweight.
This matters for Medicare because the Part D exclusion targets drugs prescribed for weight loss. When a doctor prescribes Wegovy to reduce cardiovascular risk rather than to manage weight, the legal basis for denying coverage becomes much weaker. Part D plans can potentially cover the drug under this cardiovascular indication, since preventing heart attacks and strokes is clearly a medical use that falls outside the weight loss exclusion.
To qualify under this pathway, you would generally need to have a documented history of cardiovascular disease (such as a prior heart attack, stroke, or known artery disease) along with a BMI in the overweight or obese range. Your doctor would need to prescribe Wegovy specifically for cardiovascular risk reduction, not weight management.
What You’ll Likely Pay If Covered
Even when Medicare Part D does cover anti-obesity medications, costs vary significantly depending on your plan type and income level. For anti-obesity drugs broadly, Part D enrollees paid an average of $60 out of pocket for a one-month supply in 2023, though the majority of patients paid $15 or less per month. The wide gap between average and typical costs reflects the fact that a smaller number of enrollees face much higher bills, pulling the average up.
Your plan type also matters. Enrollees in Medicare Advantage plans with drug coverage paid about 44 percent less per monthly supply compared to those in standalone Part D plans.
Annual costs tell a sharper story. Non-low-income enrollees spent an average of $651 per year on these medications, while those receiving low-income assistance paid just $22 annually.
How Extra Help Reduces Costs
Medicare’s Extra Help program (also called the Low-Income Subsidy) dramatically lowers drug costs for people with limited income and resources. If you qualify, you pay no plan premium, no deductible, and sharply reduced copays for each prescription: up to $5.10 for generic drugs and up to $12.65 for brand-name drugs in 2026.
Once your total drug costs for the year reach $2,100 (including payments made on your behalf through Extra Help), you pay nothing for covered drugs for the rest of the year. If you also have full Medicaid coverage and are in the Qualified Medicare Beneficiary program, your copay drops to no more than $4.90 per covered drug. For someone on a monthly injection like Wegovy, these savings can amount to thousands of dollars annually compared to paying out of pocket.
Legislation That Could Expand Coverage
The Treat and Reduce Obesity Act of 2023 aims to remove the Part D exclusion on anti-obesity medications entirely, which would allow Medicare to cover Wegovy for weight loss, not just cardiovascular protection. The bill was reported out of the House Ways and Means Committee in late December 2024, but it has not been signed into law. If it passes, Medicare beneficiaries could get coverage for Wegovy based on obesity alone, without needing a separate cardiovascular diagnosis.
Until that legislation moves forward, the cardiovascular indication remains the only reliable route to Medicare coverage for Wegovy. If you have heart disease and are living with obesity or overweight, talk to your prescriber about whether the cardiovascular indication applies to your situation. If you’re seeking Wegovy purely for weight management, Medicare will not cover it under current law.